Selank, pinealon and PE-22-28 blend

This three-peptide stack is marketed for calm, focus and mood. One component has small, mostly Russian human studies; the other two have essentially none. Combining them multiplies the unknowns.

As sold, one vial: Selank 5 mg, Pinealon 5 mg, PE-22-28 5 mg. Statuses as of October 3, 2026. Reviewed by the Grey Peptides Editorial Board. Nothing here is a recommendation or a dose, and no seller is named or linked.

Each component at a glance

From our encyclopedia and FDA's July 2026 Pharmacy Compounding Advisory Committee record. Evidence grades follow the rubric on our methodology page.

What one vial contains: the ratio arithmetic

The vial holds 15 mg in total. Whatever volume of water is added and however much is drawn, every draw carries the components in the same proportions. The table expresses each as a share of the vial, as a multiple of the smallest component (Selank), and as a concentration if the whole vial were dissolved in 2 mL or 3 mL of water. These are arithmetic illustrations of what is in the vial, not suggested volumes or doses.

The Blend & Stack Calculator runs the same arithmetic for any volume and draw, with this composition as a preset (Selank, pinealon and PE-22-28, 15 mg (5/5/5), example composition).

Selank on its own

Selank is a synthetic peptide developed in Russia as an anti-anxiety drug and approved there¹. Its human studies are small and mostly open-label: in 62 patients with generalised anxiety or neurasthenia, selank and medazepam had similar anti-anxiety effects (human study)²; in 60 patients with phobic-anxiety and somatoform disorders, it showed anti-anxiety and mild nootropic effects (human study)³; and added to phenazepam in 70 patients, it sped the response and reduced some side effects (human study)⁴. In 52 healthy people, brain imaging found short-term changes in connectivity (human study)⁵. A 2021 review called selank a poorly studied Russian drug sold to US consumers as a supplement (review)⁶.

Pinealon on its own

Pinealon is a three-amino-acid peptide (Glu-Asp-Arg) from the St. Petersburg 'bioregulator' series¹. In cells, it limited the build-up of reactive oxygen species and reduced necrotic cell death under oxidative stress (laboratory study)⁷. Human data are limited to small Russian reports, such as a study of 32 people aged 41 to 83 with organic brain syndrome given pinealon or vesugen, where the authors reported effects on biological-age measures and found vesugen's effect more visible (human study)⁸, and a review of neuroprotective peptides in elderly people (review)⁹. It is not approved in the US¹.

PE-22-28 on its own

PE-22-28 is a seven-amino-acid peptide designed from spadin, a natural peptide derived from the sortilin receptor that blocks the TREK-1 potassium channel, a target linked to depression in mice (animal study)¹⁰. In 2017 its developers reported that PE-22-28 blocked TREK-1 more potently than spadin, reduced immobility in the forced-swim test in mice, induced neurogenesis after four days, and lasted up to 23 hours in the body against 7 for spadin (laboratory and animal study)¹¹. There is no human study, and it is not approved¹.

Why the stack has no trial

The three act through different routes: selank is linked to GABA systems and to slowing enkephalin breakdown⁶¹², pinealon is proposed to act on cell stress and gene expression⁷, and PE-22-28 blocks a potassium channel¹¹. No study has tested any two of them together, let alone all three, in people or animals. For a stack aimed at mood, that matters: changing several brain systems at once can produce effects no single component shows, and an injected combination makes any reaction impossible to attribute.

What the ratio means

With 5 mg of each in our example, as the table above shows, every draw holds equal milligrams of three peptides whose potencies differ enormously: PE-22-28 blocked its target at sub-nanomolar concentrations in cells¹¹, while the others have no comparable potency measure in people. Equal milligrams are not equal effects. Our Blend Calculator shows the arithmetic; it describes content, not a dose.

Interactions and cautions

Selank was studied alongside the benzodiazepine phenazepam⁴, and a review grouped it with GABA-acting sedatives⁶, so anyone on sedatives, sleeping pills or alcohol should be cautious. Combining an untested antidepressant-like channel blocker with other mood-active compounds, or with prescribed antidepressants, has no safety data at all. None of the three has been fully reviewed in our interaction matrix¹.

Regulatory status in the United States

None of the three is FDA-approved. Selank is approved only in Russia; pinealon is marketed there as a supplement-type bioregulator; PE-22-28 is preclinical¹.

For tested athletes

In our tracker, pinealon and PE-22-28 fall under WADA's S0 by inference as unapproved substances, and selank's status is unsettled because of its Russian approval¹. A product containing all three should be treated as prohibited.

What to check before anything else

Anxiety and low mood have effective, approved treatments, and a doctor can help find the right one. Our semax vs selank comparison covers selank in more depth. If you are considering this stack, ask for a certificate that quantifies each of the three peptides separately, and do not combine it with sedatives or antidepressants without medical advice.

Sources

1. Grey Peptides encyclopedia entries for selank (approved in Russia; WADA unsettled), pinealon and PE-22-28 (not approved; WADA S0 inferred), including interaction coverage. Read October 3, 2026.
2. Zozulia, A. A., et al. (2008). [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova, 108. PubMed 18454096 ↗
3. Medvedev, V. E., et al. (2014). [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zh Nevrol Psikhiatr Im S S Korsakova, 114. PubMed 25176261 ↗
4. Medvedev, V. E., et al. (2015). [Optimization of the treatment of anxiety disorders with selank]. Zh Nevrol Psikhiatr Im S S Korsakova, 115. PubMed 26356395 ↗
5. Panikratova, Y. R., et al. (2020). Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci, 490. PubMed 32342318 ↗
6. Doyno, C. R., et al. (2021). Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol, 61 Suppl 2. PubMed 34396551 ↗
7. Khavinson, V., et al. (2011). Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res, 14. PubMed 21978084 ↗
8. Meshchaninov, V. N., et al. (2015). [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. Adv Gerontol, 28. PubMed 26390612 ↗
9. Umnov, R. S., et al. (2013). [Neuroprotective effects of peptides bioregulators in people of various age]. Adv Gerontol, 26. PubMed 24738258 ↗
10. Mazella, J., et al. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol, 8. PubMed 20405001 ↗
11. Djillani, A., et al. (2017). Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol, 8. PubMed 28955242 ↗
12. Zozulya, A. A., et al. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med, 131. PubMed 11550013 ↗

Related: the blends and stacks hub, the Name Decoder, the COA Decoder and the Interaction Matrix. Last updated October 3, 2026.